Corrigendum to "Bacterial mutagenicity screening in the pharmaceutical industry" [Mutat. Res. 752(2) (2013) 99-118]
Mutat Res
.
2013 Oct-Dec;753(2):155.
doi: 10.1016/j.mrrev.2013.09.003.
Epub 2013 Oct 4.
Authors
P A Escobar
1
,
R A Kemper
2
,
J Tarca
2
,
J Nicolette
3
,
M Kenyon
4
,
S Glowienke
5
,
S G Sawant
6
,
J Christensen
7
,
T E Johnson
7
,
C McKnight
7
,
G Ward
7
,
S M Galloway
7
,
L Custer
8
,
E Gocke
9
,
M R O'Donovan
10
,
K Braun
11
,
R D Snyder
12
,
B Mahadevan
7
Affiliations
1
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877-0368, USA. Electronic address:
[email protected]
.
2
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877-0368, USA.
3
AbbVie, Abbott Park, IL 60064-3500, USA.
4
Pfizer Global Research and Development, Groton, CT, USA.
5
Novartis Pharma AG, Werk Klybeck Klybeckstrasse 141, Basel CH-4057, Switzerland.
6
Amgen Inc., Thousand Oaks, CA 91320-1799, USA.
7
Merck Research Laboratories West Point, PA 19486, USA.
8
Bristol Myers-Squib, New Brunswick, NJ 08903, USA.
9
Hoffman-La Roche Ltd., Basel, Switzerland.
10
AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
11
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt, Germany.
12
Merck Research Laboratories West Point, PA 19486, USA; RDS Consulting Services, Maineville, OH 45039, USA.
PMID:
33348475
DOI:
10.1016/j.mrrev.2013.09.003
No abstract available
Publication types
Published Erratum